Thrombopoietic cytokine and P-selectin levels in patients with multiple myeloma undergoing autologous stem cell transplantation: Decrease in posttransplantation P-selectin levels might predict the degree of maximum response

Clinical Lymphoma and Myeloma

Volumn 9, Issue 3, 2009, Pages 229-233

  Aki, Sahika Zeynep ^a   Şucak, Gülsan Türköz ^a   Paşaoǧlu, Hatice ^a   Özkurt, Zübeyde Nur ^a   Yegin, Zeynep Arzu ^a   Ofluoǧlu, Ebru ^a   Yaǧci, Münci ^a   Haznedar, Rauf ^a  

^a GAZI UNIVERSITY   (Turkey)

Author keywords

Hematopoietic stem cell transplantation; IL 6; Platelet engraftment; Soluble P selectin; Thrombopoietin; TPO

Indexed keywords

CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; INTERLEUKIN 11; INTERLEUKIN 1BETA; INTERLEUKIN 6; MELPHALAN; PADGEM PROTEIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; THALIDOMIDE; THROMBOPOIETIN; VINCRISTINE; CYTOKINE;

ADULT; AGED; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BLOOD LEVEL; CLINICAL ARTICLE; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; MEGAKARYOPOIESIS; MULTIPLE MYELOMA; PATHOGENESIS; PERIPHERAL BLOOD STEM CELL; REMISSION; THROMBOCYTE; TREATMENT RESPONSE; AUTOTRANSPLANTATION; BIOSYNTHESIS; METABOLISM; METHODOLOGY; MIDDLE AGED; STEM CELL TRANSPLANTATION; THROMBOCYTOPOIESIS;

ADULT; AGED; CYTOKINES; FEMALE; HUMANS; INTERLEUKIN-11; INTERLEUKIN-1BETA; INTERLEUKIN-6; MALE; MIDDLE AGED; MULTIPLE MYELOMA; P-SELECTIN; REMISSION INDUCTION; STEM CELL TRANSPLANTATION; THROMBOPOIESIS; TRANSPLANTATION, AUTOLOGOUS;

EID: 69149107338     PISSN: 15579190     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2009.n.045     Document Type: Article

References (38)

1. Attal M, Moreau P, Avet-Loiseau H, et al. Stem cell transplantation in multiple myeloma. Blood 2007; 311-6.
2. Attal M, Harousseau JL, Stoppa AM, et al. A prospective randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myeloma. N Engl J Med 1996; 335:91-7.
3. Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem cell rescue for multiple myeloma. N Engl J Med 2003; 348:1875-83.
4. Lauta VM. A review of the cytokine network in multiple myeloma. Diagnostic, prognostic, and therapeutic implications. Cancer 2003; 97:2440-52.
5. Merico F, Bergui L, Gregoretti MG, et al. Cytokines involved in the progression of multiple myeloma. Clin Exp Immunol 1993; 92:27-31.
6. Lust JA. Donovan Ka. The role of interleukin-1? in the pathogenesis of multiple myeloma. Hematol Oncol Clin North Am 1999; 13:1117-25.
7. Carter A, Merchav S, Silvian-Draxler I, et al. The role of interleukin-1 and tumour necrosis factor-? in human multiple myeloma. Br J Haematol 1990; 74:424-31.
8. Wierzbowska A, Urbanska-Rys H, Robak T. Circulating IL-6-type cytokines and sIL-6R in patients with multiple myeloma. Br J Haematol 1999; 105:412-9.
9. Zhang XG, Gu JJ, Lu ZY, et al. Ciliary neurotropic factor, interleukin-11, leukemia inhibitory factor, and oncostatin M are growth factors for human myeloma cell lines using the interleukin 6 signal transducer GP130. J Exp Med 1994; 177:1337-42.
10. Su RJ, Li K, Yang M, et al. Platelet-derived growth factor enhances ex vivo expansion of megakaryocytic progenitors from human cord blood. Bone Marrow Transplant 2001; 27:1075-80.
11. Usuki K, Tahara T, Iki S, et al. Serum thrombopoietin level in various hematological diseases. Stem Cells 1996; 14:558-65.
12. Testa U, Martucci R, Rutella S, et al. Autologous stem cell transplantation: Release of early and late acting growth factors relates with hematopoietic ablation and recovery. Blood 1994; 84:3532-9.
13. Shimazaki C, Inaba T, Uchiyama H, et al. Serum thrombopoietin levels in patients undergoing autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 1997; 19:771-5.
14. Wagemaker G, Neelis KJ, Hartong SC, et al. The efficacy of recombinant thromboietin in murine and nonhuman primate models for radiation-induced myelosuppression and stem cell transplantation. Stem Cells 1998; 16:375-86.
15. Bladé J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplantation. Br J Haematol 1998; 102:1115-23.
16. Vadhan-Raj Saroj, Murray LJ, Bueso-Ramos C, et al. Stimulation of megakaryocyte and platelet production by a single dose of recombinant human thrombopoietin in patients with cancer. Ann Hematol 1997; 126:673-81.
17. Linker C, Anderlini P, Herzig R, et al. Recombinant human thrombopoietin augments mobilization of peripheral blood progenitor cells for autologus transplantation. Biol Blood Marrow Transplant 2003; 9:405-13.
18. Folman CC, de Jong CM, de Haas M. In multiple myeloma increased thrombopoietin (Tpo) production may be involved in the maintenance of platelet production. Eur J Haematol 2001; 66:337-41.
19. Steffen M, Dürken M, Pichlmeier U, et al. Serum interleukin-6 levels during bone marrow transplantation: impact on transplant-related toxicity and ngraftment. Bone Marrow Transplant 1996; 18:301-7.
20. Ferra C, de Sanjose S, Gallardo D, et al. IL-6 and IL-8 levels in plasma during hematopoietic progenitor transplantation. Hamatologica 1998; 83:1082-7.
21. Lacy MQ, Donovan KA, Heimbach JK, et al. Comparison of interleukin-1? expression by in situ hybridization in monoclonal gammopathy of undetermined significance and multiple myeloma. Blood 1999; 93:300-5.
22. Lost JA, Donovan KA. The role of interleukin-1? in the pathogenesis of multiple myeloma. Hematol/Oncol Clin North America 1999; 13:1117-25.
23. Kaser A, Brandacher G, Steurer W, et al. Interleukin-6 stimulates thrombopoiesis through thrombopoietin: role in inflammatory thrombocytosis. Blood 2001; 98:2720-5.
24. Kawano Y, Takaue Y, Saito S, et al. Granulocyte colony-stimulating factor (CSF), macrophage-CSF, granulocyte-macrophage CSF, interleukin-3, and interleukin-6 levels in sera from children undergoing blood stem cell autografts. Blood 1993; 81:856-60.
25. Morrell CN, Sun H, Swaim AM, et al. Platelets and inflammatory force in transplantation. Am J Transplant 2007; 7:2447-54.
26. Dymicka-Piekarska V, Matowicka-Karna J, Gryko M, et al. Relationship between soluble p-selectin and inflammatory factors (interleukin-6 and C-reactive protein) in colorectal cancer. Thromb Res 2007; 120:585-90.
27. Sierko E, Wojtukiewicz MZ. Platelets and angiogenesis in malignancy. Semin Thromb Hemost 2004; 30:95-108.
28. Blann AD, Gurney D, Wadley M, et al. Increased soluble P-selectin in patients with haematological and breast cancer: a comparison with fibrinogen, plasminogen activator inhibitor and von Willebrand factor. Blood Coagul Fibrinolysis 2001; 12:43-50.
29. Oh HS, Choi JH, Park CK, et al. Comparison of microvessel density before and after peripheral blood stem cell transplantation in multiple myeloma patients and its clinical implications: multicenter trial. Int J Hematol 2002; 76:465-70.
30. Egami K, Murohara T, Aoki M, et al. Ischemia-induced angiogenesis: role of inflammatory response mediated by p-selectin. J Leukoc Biol 2006; 79:971-6.
31. Florena AM, Tripodo C, Miceli L, et al. Identification of CD162 in plasma cell dyscrasia. Lancet Oncol 2005; 6:632.
32. Lenhoff S, Hjorth M, Turesson I, et al, for the Nordic Myeloma Study Group. Intensive therapy for multiple myeloma in patients younger than 60 years. Longterm results focusing on the effect of the degree of response on survival and relapse pattern after transplantation. Haematologica 2006; 9:1228-33.
33. Van de Velde HJ, Liu X, Chen G, et al. Complete response correlates with longterm survival and progression-free survival in high-dose therapy in multiple myeloma. Haematologica 2007; 92:1399-406.
34. Lahuerta JJ, Lopez JM, de la Serna J, et al for the GETH and PETHEMA Groups. Remission status defined by immunofixation vs. electrophoresis after autologous transplantation has a major impact on the outcome of multiple myeloma patients. Br J Haematol 2000; 109:438-46.
35. O'Shea D, Giles C, Terpos E, et al. Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: a single-center experience in 211 patients. Bone Marrow Transplant 2006; 37:731-7.
36. Alexanian R, Weber D, Giralt S, et al. Impact of complete remission with intensive therapy in patients with responsive multiple myeloma. Bone Marrow Transplant 2001; 27:1037-43.
37. Rajkumar SV, Fonseca R, Dispenzieri A, et al. Effect of complete response on outcome following autologous stem cell transplantation for myeloma. Bone Marrow Transplant 2000; 26:979-83.
38. Barlogie B, Anaissie E, Haessler J, et al. Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myeloma. Cancer 2008; 113:355-9.